ENAC Blockade and Arterial Stiffness

Insulin Resistance Clinical Trial

Official title:

Estrogen Receptor Alpha Signaling in Endothelial Cells Exacerbates Arterial Stiffening Via Upregulation of ENaC in Insulin Resistant Females

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03837626
• Other study ID #: 2012990
• Status: Active, not recruiting
• Phase: Phase 2/Phase 3
• Start date: July 15, 2019
• Est. completion date: June 2024

Study information

• Verified date: June 2024
• Source: University of Missouri-Columbia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine whether treatment with the ENaC inhibitor, amiloride, improves endothelial function and arterial stiffness in obese insulin resistant subjects in a randomized placebo-controlled trial examining pre and postmenopausal women and age-matched men.

Description:

Overweight/obese males, pre- and post-menopausal females with insulin resistance, 30-70 years of age will be recruited. Following screening, eligible men and women will be randomly assigned to either amiloride (max dose 5mg) or placebo in a double-blinded design manner.

After randomization, subjects will be scheduled for an outpatient visit to the undergo baseline assessment of arterial stiffness (carotid femoral pulse wave velocity - cfPWV) and endothelial function (brachial popliteal artery flow mediated dilation). Subject assessment will be repeated at 12 weeks and at 24 weeks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 157
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• 30 to 70 years of age at randomization

• Body mass index (BMI) 25.1-50 kg/m2 or waist circumference > 88 cm (> 35 in) in women and >102 cm (>40 in) in men. 3, 4

• One other characteristic of metabolic syndrome (elevated triglycerides =150 mg/dl; HDL cholesterol <40 mg/dl in men and <50 mg/dl in women; blood pressure =130/85 mm Hg or treatment for hypertension; impaired fasting glucose (=100 mg/dl)) or fasting insulin level >10 mU/L (correlates with insulin resistance).

Exclusion Criteria:

1. History of type 1 or type 2 diabetes

2. Known cardiovascular events within the last 12 months (stroke, acute coronary event, revascularization, heart failure hospitalization).

3. History of uncontrolled thyroid disease, chronic liver disease (cirrhosis) or GFR <50 ml/min.

4. Use of potassium sparing medications (angiotensin II receptor blockers, angiotensin converting enzymes inhibitors or mineralocorticoid receptor blockers) or use of potassium supplements.

5. Active cancer (This criterion does not apply to those subjects with basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)

6. Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)

7. Current tobacco use

8. Non controlled hypertension

9. Participation in regular exercise > 3 days/wk per week at a moderate or vigorous intensity

10. Pregnancy or lactation in women (or women not using contraceptives)

11. Women who plan to become pregnant during the duration of the trial

12. Chronic use of NSAIDs

13. Potassium level > 5.0 mqE/L at time of screening

14. Blood pressure at screening <110/70

Related Conditions & MeSH terms

• Insulin Resistance
• Overweight
• Overweight and Obesity

Intervention

Drug:
• Placebo - Cap
6 months of 1 pill a day
• Amiloride Pill
Max dose of 5 mg a day for 6 months

Locations

Country	Name	City	State
United States	University of Missouri Hospital and Clinics	Columbia	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
University of Missouri-Columbia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Carotid femoral PWV	It is the gold standard non-invasive index of arterial stiffness. Transit time between carotid and femoral pressure waves is calculated using the foot-to-foot method. cfPWV is calculated as distance traveled by the pulse wave (i.e., femoral location-sternal notch minus sternal notch-carotid location) divided by pulse transit time. All the measurements will be done by the same blinded technician.The goal is to assess changes from baseline when compared to interim and final time point.	Baseline, 3 months (interim) and 6 months (final)
Secondary	Brachial artery flow mediated dilation (FMD)	The goal is to assess changes from baseline when compared to interim and final time point. ] Brachial artery FMD will be assessed at baseline and at 12-wk. FMD is a measurement of conduit artery endothelial function. FMD is assessed immediately after each PWV measurement. Shear rate AUC until peak diameter is calculated as stimulus for FMD and used in covariate analysis as described. All measurements will be performed, under co-I supervision by the same blinded technician.	Baseline, 3 months (interim) and 6 months (final)
Secondary	Popliteal artery flow mediated dilation (FMD)	The goal is to assess changes from baseline when compared to interim and final time point. ] Popliteal artery FMD will be assessed at baseline and at 12-wk. FMD is a measurement of conduit artery endothelial function. FMD is assessed immediately after each PWV measurement. Shear rate AUC until peak diameter is calculated as stimulus for FMD and used in covariate analysis as described. All measurements will be performed, under co-I supervision by the same blinded technician.	Baseline, 3 months (interim) and 6 months (final)